Epilepsy Clinical Trials

• History of migraine (with or without aura) for \> 6 months before Screening according to the IHS Classification ICHD-319 specifications for pediatric migraine. History may be verified using both medical records and recall by the participant and/or participant's parent(s)/legal representative(s).

• History of 1 to 8 moderate or severe attacks per month during the 2 months prior to enrollment, with attacks lasting \> 3 hours without treatment, and attacks occurring at intervals \> 24 hours.

• Prophylactic migraine medication are permitted if the dose has been stable for at least 12 weeks prior to the Baseline Visit, and the dose is not expected to change during the course of the study.

‣ Participants may remain on one (1) medication with possible migraine prophylactic effects, excluding CGRP antagonists \[biologic or small molecule\], during the treatment phases.

⁃ Concomitant use of a CGRP antagonist, such as erenumab or fremanezumab, is prohibited.

⁃ Previously discontinued prophylactic migraine medication must have done so at least 90 days prior to the Screening Visit.

• Verbally distinguish between migraine and other types of headaches.

• Participants must have a weight \> 40 kg at the Screening Visit.

• Adequate venous access for blood sampling.

• Male and female participants ≥ 6 to \< 18 years of age (participants must not reach their 18th birthday during the study).